Immunogen (IMGN) Prices 26M Share Offering at $12.50/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
May 4, 2023 7:45 PM EDTWALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 26,000,000 shares of its common stock at a price of $12.50 per share, before underwriting discounts and commissions. The offering is expected... More
